25.76
Precedente Chiudi:
$26.34
Aprire:
$26.7
Volume 24 ore:
170.96K
Relative Volume:
0.55
Capitalizzazione di mercato:
$1.15B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+5.40%
1M Prestazione:
+3.54%
6M Prestazione:
+130.00%
1 anno Prestazione:
+127.56%
Septerna Inc Stock (SEPN) Company Profile
Nome
Septerna Inc
Settore
Industria
Telefono
650-338-3533
Indirizzo
250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO
Compare SEPN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
SEPN
Septerna Inc
|
25.76 | 1.18B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Septerna Inc Stock (SEPN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-19 | Iniziato | Raymond James | Strong Buy |
| 2025-12-15 | Iniziato | Truist | Buy |
| 2025-11-14 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-06-23 | Iniziato | H.C. Wainwright | Buy |
| 2025-02-18 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-11-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-11-19 | Iniziato | JP Morgan | Overweight |
| 2024-11-19 | Iniziato | TD Cowen | Buy |
| 2024-11-19 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Septerna Inc Borsa (SEPN) Ultime notizie
How Early SEP-631 Data at AAAAI 2026 Will Impact Septerna (SEPN) Investors - simplywall.st
Septerna to present phase 1 data for SEP-631 at AAAAI meeting - Investing.com Canada
Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Viatris Septerna BIO Takeda name new legal chiefs - BioXconomy
Early trial tests oral therapy for mast cell diseases at 2026 allergy meeting - Stock Titan
Profit Recap: How do insiders feel about AutoZone IncJuly 2025 Decliners & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Aug Breakouts: Is Septerna Inc a cyclical or defensive stockWeekly Earnings Recap & AI Driven Stock Reports - baoquankhu1.vn
Death Cross: Will Septerna Inc stock go up in YEAR2025 Macro Impact & Smart Swing Trading Alerts - baoquankhu1.vn
Septerna, Inc. (NASDAQ:SEPN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Septerna, Inc. (NASDAQ:SEPN) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Travel Stocks: Is Septerna Inc forming a bullish divergenceWeekly Profit Recap & Daily Price Action Insights - baoquankhu1.vn
Septerna (NASDAQ:SEPN) Shares Up 7.9%Still a Buy? - MarketBeat
Short Interest in Septerna, Inc. (NASDAQ:SEPN) Increases By 36.0% - MarketBeat
Septerna, Inc. (SEPN) Investor Outlook: 42% Potential Upside Amidst Breakthrough Growth In Revenue - DirectorsTalk Interviews
HC Wainwright Analysts Lower Earnings Estimates for Septerna - Defense World
Septerna: Advancing GPCR Pipeline and De-Risked Valuation Support Upgraded Buy Rating and $35 Target - TipRanks
HC Wainwright Issues Negative Forecast for Septerna Earnings - MarketBeat
Is Septerna (SEPN) Quietly Building an IP Moat with Its New Chief Legal Officer Hire? - simplywall.st
SEPN: HC Wainwright & Co. Updates Price Target to $35 | SEPN Sto - GuruFocus
Septerna stock price target raised to $35 from $30 at H.C. Wainwright - Investing.com Nigeria
The Analyst Verdict: Septerna In The Eyes Of 6 Experts - Benzinga
Aug Reactions: Does Septerna Inc have a sustainable dividendInflation Watch & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Septerna (NASDAQ:SEPN) Shares Up 7.5%Still a Buy? - MarketBeat
Septerna to Present GPCR Pipeline Updates at JPM Conference - TipRanks
Septerna, Inc. Announces Key Developments at J.P. Morgan Healthcare Conference - TradingView — Track All Markets
Assessing Septerna (SEPN) Valuation After Recent Share Price Pullback And One Year 40.63% Return - Yahoo Finance
Septerna (NASDAQ:SEPN) Downgraded to “Buy” Rating by Wall Street Zen - Defense World
Septerna, Inc. (SEPN) Stock Analysis: Unraveling a 28.76% Potential Upside in Biotechnology - DirectorsTalk Interviews
Septerna, Inc. (NASDAQ:SEPN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Septerna Appoints Mark Wilson as Chief Legal Officer - The Globe and Mail
Will Septerna Inc. stock benefit from sector rotationMarket Growth Summary & AI Enhanced Market Trend Forecasts - Улправда
Why retail investors favor Septerna Inc. stockEarnings Risk Summary & Low Drawdown Trading Techniques - Улправда
What Wall Street predicts for Septerna Inc. stock priceMarket Growth Summary & Intraday High Probability Setup Alerts - ulpravda.ru
Septerna appoints Mark Wilson as chief legal officer By Investing.com - Investing.com South Africa
Septerna appoints Mark Wilson as chief legal officer - Investing.com
Septerna, Inc. Expands Leadership with New Chief Legal Officer - TradingView — Track All Markets
Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer - The Manila Times
Septerna (NASDAQ:SEPN) Stock Price Down 6.3%What's Next? - MarketBeat
Septerna, Inc. (SEPN) Stock Analysis: Unveiling a Potential 18.88% Upside with Groundbreaking Biotech Innovations - DirectorsTalk Interviews
What analysts say about Septerna Inc stockDividend Yield Trends & AI-Based Predictions Available Free - earlytimes.in
Jones Trading initiates coverage of Septerna (SEPN) with buy recommendation - MSN
Jones Trading Initiates Coverage of Septerna (SEPN) with Buy Recommendation - Nasdaq
Septerna stock initiated with Buy rating at Jones Trading on GPCR pipeline By Investing.com - Investing.com South Africa
Septerna stock initiated with Buy rating at Jones Trading on GPCR pipeline - Investing.com Nigeria
Septerna (NASDAQ:SEPN) Coverage Initiated at Jones Trading - MarketBeat
Septerna (SEPN): Valuation Check After Raymond James Buy Rating and S&P Pharma Index Inclusion - Sahm
Septerna, Inc.(NasdaqGM: SEPN) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
Septerna, Inc.(NasdaqGM: SEPN) added to NASDAQ Biotechnology Index - marketscreener.com
Septerna’s SEP-631 Study: A Potential Game-Changer in Pharmaceutical Research - MSN
Septerna Inc Azioni (SEPN) Dati Finanziari
Non sono disponibili dati finanziari per Septerna Inc (SEPN). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):